Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALNY Alnylam Pharmaceuticals

Market Closed 12-05 16:00:00 EST

458.12

-7.22

-1.55%

盘后450.00

-8.12-1.77%

19:40 EST

High473.50	Low455.32	Vol627.35K
Open468.29	D1 Closing465.34	Amplitude3.91%
Mkt Cap60.52B	Tradable Cap57.79B	Total Shares132.11M
T/O288.09M	T/O Rate0.50%	Tradable Shares126.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALNY","market":"US","secType":"STK","nameCN":"Alnylam Pharmaceuticals","latestPrice":458.12,"timestamp":1764968400000,"preClose":465.34,"halted":0,"volume":627353,"hourTrading":{"tag":"盘后","latestPrice":450,"preClose":458.12,"latestTime":"19:40 EST","volume":32559,"amount":14910709.22,"timestamp":1764981620307},"delay":0,"floatShares":126154848,"shares":132113818,"eps":0.329855,"marketStatus":"Market Closed","change":-7.22,"latestTime":"12-05 16:00:00 EST","open":468.29,"high":473.5,"low":455.32,"amount":288093659.46594,"amplitude":0.039068,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.329855,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":465.34,"preHourTrading":{"tag":"盘前","latestPrice":468,"preClose":465.34,"latestTime":"09:06 EST","volume":59,"amount":27569.82975,"timestamp":1764943610962},"postHourTrading":{"tag":"盘后","latestPrice":450,"preClose":458.12,"latestTime":"19:40 EST","volume":32559,"amount":14910709.22,"timestamp":1764981620307},"volumeRatio":0.6381232226526758,"impliedVol":0.4498,"impliedVolPercentile":0.712},"requestUrl":"/m/hq/s/ALNY","defaultTab":"news","newsList":[{"id":"2589834579","title":"LIVE MARKETS-Marvell, Carvana among top candidates for S&P 500 additions  - Stephens","url":"https://stock-news.laohu8.com/highlight/detail?id=2589834579","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589834579?lang=en_us&edition=fundamental","pubTime":"2025-12-05 03:15","pubTimestamp":1764875738,"startTime":"0","endTime":"0","summary":"FRESH LABOR NUMBERS, STALE FACTORY DATA CLICK HERE. US EQUITIES CHOP AROUND FLAT AFTER MIXED BAG OF DATA. S&P 500 WITHIN STRIKING DISTANCE OF ITS RECORD HIGHS CLICK HERE. BEFORE THE BELL: FUTURES RISE, BRITISH LAND TO JOIN FTSE CLICK HEREDAY OFF FOR DOLLAR DEBASEMENT TRADE CLICK HERE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nL6N3XA12F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRT","LU0476273544.USD","LU2764263203.CNY","IE00BN0W2T93.GBP","LU2098885051.SGD","LU2361045086.USD","SG9999000418.SGD","LU2048586759.USD","LU2764263039.SGD","BK4595","LU2244417387.USD","STRK","CVNA","LU1880398554.USD","BK4135","LU1039938227.USD","CRH","LU2461242641.AUD","LU1861220033.SGD","LU0029864427.USD","BK4011","BK4503","LU1267930573.SGD","LU1093756168.USD","LU0154236417.USD","IE00B64PRP62.GBP","IE00BMPRXR70.SGD","LU1989764664.SGD","LU2360108059.USD","LU2543165471.USD","IE00BMPRXQ63.HKD","MRVL","ARES","LU1093756325.SGD","BK4096","LU2249611893.SGD","LU2357305700.SGD","LU0171281750.USD","LU2458330169.SGD","GB00BDT5M118.USD","LU1992135472.HKD","LU2298321311.HKD","LU2931357623.SGD","LU1923622614.USD","ALNY","LU1894683348.USD","LU1363072403.SGD","LU1169589451.USD"],"gpt_icon":1},{"id":"2588049191","title":"Alnylam Pharmaceuticals Announces Changes To Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2588049191","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588049191?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:16","pubTimestamp":1764767807,"startTime":"0","endTime":"0","summary":"Dec 3 (Reuters) - Alnylam Pharmaceuticals Inc ::*ALNYLAM PHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORS  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 03-DEC-202513:00:02.017 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nRSD40L3sQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0889565916.HKD","BK4588","LU0114720955.EUR","BK4548","LU0882574055.USD","BK4139","LU0109394709.USD","ALNY","BK4585"],"gpt_icon":0},{"id":"2588046722","title":"Alnylam Pharmaceuticals Appoints Stuart Arbuckle to Board as Mike Bonney and Carolyn Bertozzi Step Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046722","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588046722?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:01","pubTimestamp":1764766879,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals Inc. announced that Mike Bonney and Carolyn Bertozzi, Ph.D., will step down from its Board of Directors effective December 2, 2025. Stuart Arbuckle has been appointed as a new independent director, effective January 5, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire  on December 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDLHjbDj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4548","LU0882574055.USD","BK4585","BK4139","LU0114720955.EUR","LU0320765992.SGD","ALNY","BK4588","LU0889565916.HKD"],"gpt_icon":0},{"id":"2588248046","title":"Alnylam Pharmaceuticals Announces Changes to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2588248046","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588248046?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:00","pubTimestamp":1764766805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUA8LHNWQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","BK4139","LU0114720955.EUR","ALNY","BK4588","LU0882574055.USD","LU0889565916.HKD","LU0109394709.USD","BK4585","LU0320765992.SGD"],"gpt_icon":0},{"id":"2588708645","title":"These Stocks Could Be Added to S&P 500 Friday in Rebalancing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588708645","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588708645?lang=en_us&edition=fundamental","pubTime":"2025-12-02 16:00","pubTimestamp":1764662400,"startTime":"0","endTime":"0","summary":"CRH, Vertiv Holdings, Alnylam Pharmaceuticals and Ares Management are top candidates for admission to the S&P 500.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4595","MSTR","LU1035777561.USD","LU1863844665.USD","LU1988902786.USD","LU0238689110.USD","LU2360108059.USD","CPNG","LU1019632923.USD","SOFI","LU0175139822.USD","LU0289960550.SGD","LU1267930573.SGD","ALNY","LU2764263039.SGD","LU2125909759.SGD","LU0171281750.USD","LU0314106906.USD","BK4585","ARES","IE00BD6J9T35.USD","LU0320765992.SGD","LNG","FERG","LU0109394709.USD","LU2463526074.USD","CVNA","LU2092937221.SGD","BK4581","BK4135","VRT","IE00BN0W2V16.EUR","BK4516","LU2720916845.USD","LU0310800379.SGD","LU1506573853.SGD","BK4023","CRH","BK4504"],"gpt_icon":1},{"id":"2587754410","title":"The Bull Case For Alnylam Pharmaceuticals (ALNY) Could Change Following Raised Sales Guidance for Vutrisiran","url":"https://stock-news.laohu8.com/highlight/detail?id=2587754410","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587754410?lang=en_us&edition=fundamental","pubTime":"2025-11-29 11:20","pubTimestamp":1764386406,"startTime":"0","endTime":"0","summary":"Earlier this quarter, Carillon Tower Advisers highlighted Alnylam Pharmaceuticals after the company's launch of vutrisiran for transthyretin amyloidosis surpassed expectations, leading Alnylam to significantly raise its sales guidance for the therapy.\nThis upward revision in sales projections was driven by stronger-than-forecast demand, underlining Alnylam's expanding leadership in gene-silencing therapies for rare diseases.\nWe'll explore how Alnylam's raised guidance for its transthyretin...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/the-bull-case-for-alnylam-pharmaceuticals-alny-could-change-1","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/the-bull-case-for-alnylam-pharmaceuticals-alny-could-change-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALNY"],"gpt_icon":0},{"id":"2587752731","title":"What's Going On With Alnylam Stock On Friday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2587752731","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587752731?lang=en_us&edition=fundamental","pubTime":"2025-11-29 01:42","pubTimestamp":1764351720,"startTime":"0","endTime":"0","summary":"Alnylam stock climbs as earnings beat, sales soar and new Amvuttra data shows cardiac benefits, adding momentum to its strong 2025 run.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/28/Alnylam-Pharmaceuticals-Photo-via-Shutte.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/28/Alnylam-Pharmaceuticals-Photo-via-Shutte.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/large-cap/25/11/49119950/whats-going-on-with-alnylam-stock-on-friday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/large-cap/25/11/49119950/whats-going-on-with-alnylam-stock-on-friday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0889565916.HKD","BK4548","BK4139","LU0882574055.USD","ALNY","LU0114720955.EUR","BK4585","BK4588","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2586752228","title":"A Look at Alnylam Pharmaceuticals's Valuation Following Raised Sales Guidance on Vutrisiran Outperformance","url":"https://stock-news.laohu8.com/highlight/detail?id=2586752228","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586752228?lang=en_us&edition=fundamental","pubTime":"2025-11-27 19:34","pubTimestamp":1764243288,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals (ALNY) attracted attention after second-quarter sales of its vutrisiran therapy for transthyretin amyloidosis significantly exceeded expectations, leading the company to raise its guidance for the year.\nSee our latest analysis for Alnylam Pharmaceuticals.\nMomentum has been building steadily for Alnylam Pharmaceuticals, with bullish sentiment fueled by the successful rollout of vutrisiran. Over the past year, the stock’s share price has surged 90.5%, while its one-year...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/a-look-at-alnylam-pharmaceuticalss-valuation-following-raise","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/a-look-at-alnylam-pharmaceuticalss-valuation-following-raise","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALNY"],"gpt_icon":0},{"id":"2584397556","title":"Alnylam Pharmaceuticals CSO Kevin Fitzgerald Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584397556","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584397556?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:06","pubTimestamp":1763586368,"startTime":"0","endTime":"0","summary":"Kevin Joseph Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL4TnrqG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Alnylam Pharmaceuticals CSO Kevin Fitzgerald Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4588","LU0109394709.USD","LU0320765992.SGD","BK4585","LU0882574055.USD","ALNY","LU0114720955.EUR","LU0889565916.HKD","BK4139"],"gpt_icon":0},{"id":"2584852039","title":"Alnylam Pharmaceuticals (ALNY): Assessing Valuation Following Positive HELIOS-B Data on Vutrisiran Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2584852039","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584852039?lang=en_us&edition=fundamental","pubTime":"2025-11-18 11:16","pubTimestamp":1763435815,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals (ALNY) just shared new post hoc analyses from its HELIOS-B Phase 3 study at a major scientific meeting. The findings highlight positive results for its RNAi therapy, vutrisiran, in treating cardiomyopathy linked to amyloidosis and in preserving kidney function.\nSee our latest analysis for Alnylam Pharmaceuticals.\nThe recent HELIOS-B data presentation seems to have sparked fresh interest in Alnylam Pharmaceuticals, with the stock notching a 2.53% gain in its latest...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylam-pharmaceuticals-alny-assessing-valuation-following-p","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylam-pharmaceuticals-alny-assessing-valuation-following-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","LU0889565916.HKD","BK4585","LU0109394709.USD","LU0114720955.EUR","LU0320765992.SGD","LU0882574055.USD","BK4548","ALNY","BK4139"],"gpt_icon":0},{"id":"2582377087","title":"Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker","url":"https://stock-news.laohu8.com/highlight/detail?id=2582377087","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582377087?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:24","pubTimestamp":1762957440,"startTime":"0","endTime":"0","summary":"In a presentation at the American Heart Association's  2025 Scientific Sessions, researchers on Tuesday shared data from Novo Nordisk A/S'  Coramitug Phase 2 trial for transthyretin amyloidosis with cardiomyopathy .The phase 2 trial showed that coramitug, an antibody targeting misfolded transthyretin in ATTR-CM, was well tolerated.A dose of 60 mg/kg resulted in a statistically significant reduction in NT-proBNP, a validated marker of disease progression, with no statistically significant effect on the six-minute walk test  within 52 weeks.Also Read: Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance. Coramitug is a humanized monoclonal antibody that targets misfolded transthyretin, designed to promote clearance of transthyretin amyloid through antibody-mediated phagocytosis.The change in 6MWT from baseline to week 52 was not statistically different from placebo with either dose. Coramitug 60 mg/k","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/12/Novo-Nordisk.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/12/Novo-Nordisk.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/11/48803144/novo-nordisks-100-million-coramitug-shows-promise-in-reducing-heart-failure-biomarker","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/11/48803144/novo-nordisks-100-million-coramitug-shows-promise-in-reducing-heart-failure-biomarker","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4007","LU0320765992.SGD","LU0154236417.USD","IE00BKVL7J92.USD","LU0868494617.USD","SG9999002224.SGD","IE00BLSP4452.SGD","BK4588","BK4534","ALNY","IE0002270589.USD","IE00BLSP4239.USD","LU1093756168.USD","LU1023059063.AUD","LU0289739699.SGD","LU0234572021.USD","NVO","SG9999001176.USD","SG9999002232.USD","LU0306807586.USD","IE00B19Z3B42.SGD","BK4568","BK4599","LU1066051498.USD","LU1894683348.USD","LU1093756325.SGD","BK4550","LU0109394709.USD","BK4139","LU0306806265.USD","LU0321505868.SGD","LU1883839398.USD","SG9999011175.SGD","PRTA","SG9999001176.SGD","LU0882574055.USD","LU1066053197.SGD","LU0225771236.USD","SG9999003800.SGD","BK4532","IE00BZ1G4Q59.USD","IE00BBT3K403.USD","BK4581","BK4548","LU0321505439.SGD","BK4585","SG9999013999.USD","LU0122379950.USD","LU0225284248.USD"],"gpt_icon":1},{"id":"2582367690","title":"Alnylam Pharmaceuticals Is Maintained at Equal-Weight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2582367690","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582367690?lang=en_us&edition=fundamental","pubTime":"2025-11-11 22:33","pubTimestamp":1762871580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2025 09:33 ET (14:33 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2461242641.AUD","BK4139","LU0130102774.USD","LU0256863811.USD","IE00B19Z3581.USD","LU0128525929.USD","LU1267930573.SGD","LU0109394709.USD","LU0868494617.USD","LU2361044949.HKD","LU0310799852.SGD","LU0320765992.SGD","LU0310800965.SGD","BK4501","LU0211328371.USD","LU0640476718.USD","LU2361044865.SGD","LU1506573853.SGD","LU0070302665.USD","LU0106831901.USD","LU0882574055.USD","LU1201861249.SGD","LU1814569148.SGD","LU0708994859.HKD","IE000M9KFDE8.USD","LU0289960550.SGD","LU0175139822.USD","LU0029864427.USD","LU0154236417.USD","LU0130517989.USD","LU0980610538.SGD","LU1668664300.SGD","LU2361045086.USD","IE00B19Z3B42.SGD","LU1267930490.SGD","LU0048573561.USD","BK4548","LU0072461881.USD","BK4207","ALNY","LU0683600562.USD","LU0162691827.USD","LU0648001328.SGD","LU1791807156.HKD","LU0114720955.EUR","LU0787776722.HKD","LU0149725797.USD","BK4504","LU0477156953.USD","LU0208291251.USD"],"gpt_icon":0},{"id":"2582875153","title":"Piper Sandler Remains a Buy on Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582875153","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582875153?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:18","pubTimestamp":1762777122,"startTime":"0","endTime":"0","summary":"In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Alnylam Pharma, with a price target of $489.00. According...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-remains-a-buy-on-alnylam-pharma-alny-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-remains-a-buy-on-alnylam-pharma-alny-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","BK4585","BK4548","BK4139","LU0114720955.EUR","ALNY","LU0889565916.HKD","BK4588","LU0882574055.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2582810651","title":"Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alnylam Pharma (ALNY) and Insulet (PODD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582810651","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582810651?lang=en_us&edition=fundamental","pubTime":"2025-11-10 10:01","pubTimestamp":1762740078,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vertex Pharmaceuticals (VRTX – Research Report), A...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vertex-pharmaceuticals-vrtx-alnylam-pharma-alny-and-insulet-podd-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vertex-pharmaceuticals-vrtx-alnylam-pharma-alny-and-insulet-podd-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJT1NW94.SGD","LU0234570918.USD","IE0009355771.USD","HCSG","XBI","IE00B19Z3B42.SGD","IE00B2B36J28.USD","BK4137","LU0256863811.USD","VERX","LU2065171311.SGD","BK4533","IE00B4R5TH58.HKD","IE0002270589.USD","LU1674673428.USD","XLV","IE00BZ9MQY76.HKD","LABU","LU2236285917.USD","LU0079474960.USD","BK4581","VRTX","LU1093756168.USD","BK4588","IE00B19Z9P08.USD","LU0128526141.USD","LU1778281490.HKD","LU2065171402.SGD","LU1093756325.SGD","LU2462157665.USD","ALNY","LU1119994496.HKD","SG9999001176.USD","BK4139","LU0109394709.USD","LU0029874061.USD","LU2456880835.USD","LU1559883803.SGD","IE00BJJMRZ35.SGD","LU2237438978.USD","LU1430594728.SGD","BK4566","LU0823416689.USD","LU2065170008.USD","BK4532","LU0058720904.USD","LU2362540622.SGD","PODD","BK4082","BK4551"],"gpt_icon":0},{"id":"2582289021","title":"Alnylam announces results from post hoc analyses of HELIOS-B Phase 3 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2582289021","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582289021?lang=en_us&edition=fundamental","pubTime":"2025-11-10 01:10","pubTimestamp":1762708208,"startTime":"0","endTime":"0","summary":"Alnylam (ALNY) Pharmaceuticals announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA, an RNAi therapeutic approved...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alnylam-announces-results-from-post-hoc-analyses-of-helios-b-phase-3-study-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alnylam-announces-results-from-post-hoc-analyses-of-helios-b-phase-3-study-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","LU0109394709.USD","LU0114720955.EUR","LU0882574055.USD","ALNY","LU0889565916.HKD","BK4139","BK4585","BK4548","BK4588"],"gpt_icon":0},{"id":"2582864025","title":"BRIEF-Alnylam Pharmaceuticals Inc Says Amyloid Regression In 22% Of Vutrisiran-Treated Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2582864025","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582864025?lang=en_us&edition=fundamental","pubTime":"2025-11-09 05:59","pubTimestamp":1762639159,"startTime":"0","endTime":"0","summary":"BRIEF-Alnylam Pharmaceuticals Inc Says Amyloid Regression In 22% Of Vutrisiran-Treated PatientsNov 8 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O:ALNYLAM PHARMACEUTICALS INC - AMYLOID REGRESSION IN ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251108:nFWN3WJ29K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0109394709.USD","BK4548","BK4588","LU0114720955.EUR","LU0320765992.SGD","BK4585","LU0882574055.USD","LU0889565916.HKD","ALNY"],"gpt_icon":0},{"id":"2582640658","title":"Alnylam Pharmaceuticals Inc - Amyloid Regression in 22% of Vutrisiran-Treated Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2582640658","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582640658?lang=en_us&edition=fundamental","pubTime":"2025-11-09 05:58","pubTimestamp":1762639101,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251108:nFWN3WJ29K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","LU0882574055.USD","ALNY","BK4548","LU0109394709.USD","LU0114720955.EUR","BK4588","BK4585","LU0889565916.HKD","BK4139"],"gpt_icon":0},{"id":"2582865291","title":"Biotech stocks are coming back. Here's what's driving the sector higher.","url":"https://stock-news.laohu8.com/highlight/detail?id=2582865291","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582865291?lang=en_us&edition=fundamental","pubTime":"2025-11-09 00:57","pubTimestamp":1762621020,"startTime":"0","endTime":"0","summary":"The volatile sector is seeing greater stability, and these four stocks can profit. Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 percentage points.Biotech's strength is likely to continue - so it's not too late for investors to get in, sector analysts say.\"Biotech will be a comparative outperformer,\" says Motley Fool biotech analyst Karl Thiel. \"There is better sentiment and fund-flow, and that feeds on itself. That can unravel quickly but I still think it has some legs.\". Stifel's head of biotech research, Paul Matteis, agrees. \"The sector's run has been driven by a number of credible fundamental factors that seem mostly sustainable,\" he said in a recent interview.M&A also puts higher valuations on biotech companies in general because investors start considering how much more profitable potential drugs might be in the hands of companies ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASND","LU0786609619.USD","LU2106854487.HKD","LU2237443622.USD","PRAX","ABBV","LU0985481810.HKD","LU2168563687.JPY","LU0553294199.USD","LU2129689514.USD","LU0965509101.SGD","ARGX","LU1267930490.SGD","RAPP","LU1366192091.USD","LU1894683264.USD","IE00B19Z3B42.SGD","SGXZ81514606.USD","LU0321505439.SGD","BBIO","SG9999001440.SGD","QURE","ALNY","BK4585","SG9999014906.USD","LU0471298694.HKD","LU2237443978.SGD","MDGL","BMY","LU2552382058.USD","AMGN","LU1839511570.USD","LU2242646821.SGD","BK4548","NBIX","LU1093756325.SGD","MBX","IE00BGHQF631.EUR","LU1623119135.USD","ALKS","LU2360106947.USD","SG9999002232.USD","LU0097036916.USD","LU0689626769.HKD","LU2237443549.SGD","LU2237443382.USD","BK4559","LU0545039389.USD"],"gpt_icon":1},{"id":"2580310957","title":"Alnylam Pharmaceuticals to Present at UBS Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2580310957","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580310957?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:01","pubTimestamp":1762261312,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals Inc. will present a company overview at the UBS Global Healthcare Conference on November 10, 2025, in Palm Beach Gardens, Florida. The company's management will also present at the Jefferies Global Healthcare Conference on November 19, 2025, in London. Audio webcasts of both presentations will be available on the Alnylam website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire  on November 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL5MKLQy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4548","ALNY","LU0882574055.USD","LU0109394709.USD","LU0320765992.SGD","BK4588","BK4585","LU0889565916.HKD","LU0114720955.EUR"],"gpt_icon":0},{"id":"2580373638","title":"Royalty Pharma Buys $310 Million AMVUTTRA Royalty from Blackstone","url":"https://stock-news.laohu8.com/highlight/detail?id=2580373638","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580373638?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:15","pubTimestamp":1762258522,"startTime":"0","endTime":"0","summary":"Royalty Pharma plc has acquired a 1% royalty interest in Alnylam's AMVUTTRA from Blackstone Life Sciences for $310 million. The royalty covers worldwide net sales of AMVUTTRA from October 1, 2025, through March 2035. AMVUTTRA, an FDA-approved RNAi therapeutic for ATTR amyloidosis, reached about $1 billion in sales in 2024 and is projected to exceed $6 billion by 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royalty Pharma plc published the original content used to generate this news brief via GlobeNewswire  on November 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL9hgM7x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU2210150020.SGD","IE00B64PRP62.GBP","NDAQ","LU0114720955.EUR","IE00BGHQF748.EUR","BK4007","IE00BKPKM429.USD","BK4112","LU2095319765.USD","LU0109394709.USD","BK4588","LU0889565916.HKD","LU0320765992.SGD","LU0314104364.USD","ALNY","BK4548","BK4585","BK4139","LU2210149790.SGD","RPRX","IE00B3QW5Z07.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alnylam.com","stockEarnings":[{"period":"1week","weight":0.0153},{"period":"1month","weight":0.0542},{"period":"3month","weight":0.0135},{"period":"6month","weight":0.5229},{"period":"1year","weight":0.8193},{"period":"ytd","weight":0.9469}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.52381,"avgChangeRate":0.037108},{"month":2,"riseRate":0.47619,"avgChangeRate":0.003609},{"month":3,"riseRate":0.47619,"avgChangeRate":-0.013154},{"month":4,"riseRate":0.380952,"avgChangeRate":-0.019703},{"month":5,"riseRate":0.619048,"avgChangeRate":0.04124},{"month":6,"riseRate":0.636364,"avgChangeRate":0.064494},{"month":7,"riseRate":0.681818,"avgChangeRate":0.106925},{"month":8,"riseRate":0.590909,"avgChangeRate":0.037005},{"month":9,"riseRate":0.545455,"avgChangeRate":0.034409},{"month":10,"riseRate":0.409091,"avgChangeRate":-0.042013},{"month":11,"riseRate":0.727273,"avgChangeRate":0.078577},{"month":12,"riseRate":0.5,"avgChangeRate":0.012348}],"exchange":"NASDAQ","name":"Alnylam Pharmaceuticals","nameEN":"Alnylam Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alnylam Pharmaceuticals,ALNY,Alnylam Pharmaceuticals股票,Alnylam Pharmaceuticals股票老虎,Alnylam Pharmaceuticals股票老虎国际,Alnylam Pharmaceuticals行情,Alnylam Pharmaceuticals股票行情,Alnylam Pharmaceuticals股价,Alnylam Pharmaceuticals股市,Alnylam Pharmaceuticals股票价格,Alnylam Pharmaceuticals股票交易,Alnylam Pharmaceuticals股票购买,Alnylam Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction